Phase III study with FOLFIRI + cetuximab versus FOLFIRI + cetuximab followed by cetuximab alone in RAS and BRAF WT mCRC. (30th May 2018)

• Record Type: Journal Article
• Authors: Pinto, Carmine; Normanno, Nicola; Orlandi, Armando; Fenizia, Francesca; Damato, Angela; Maiello, Evaristo; Tamburini, Emiliano; Di Costanzo, Francesco; Tonini, Giuseppe; Bilancia, Domenico; Corsi, Domenico; Pisconti, Salvatore; Ferrau, Francesco; Gori, Stefania; Daniele, Bruno; Zaniboni, Alberto; Soto Parra, Héctor; Frassinetti, Giovanni Luca; Iaffaioli, Rosario Vincenzo; Cassata, Antonio; Zampino, Maria Giulia; Repetto, Lazzaro; Calegari, Maria Alessandra; Barone, Carlo
• Is Part Of: Future oncology. Volume 14:Number 14(2018)
• Page Start: 1339
• Page End: 1346
• Publication Date: 2018-05-30
• Subjects: cetuximab -- colorectal cancer -- de-escalation therapy -- RAS and BRAF wild-type; Oncology -- Periodicals; 616.99405
• DOI: 10.2217/fon-2017-0592
• Languages: English
• ISSNs: 1479-6694

Abstract

The optimal duration and intensity of first-line therapy in metastatic colorectal cancer patients once they have achieved an objective response is controversial. In a molecularly selected RAS and BRAF wild-type (wt) population, this concern is amplified. Once disease control has been achieved with a combination therapy including an anti-EGFR antibody, further exposure both to cytotoxic drugs and targeted therapy might result only in increased toxicity. In unresectable metastatic RAS and BRAF wt colorectal cancer patients, a deintensified therapy could represent a valuable option that might preserve quality of life. We designed a study to compare FOLFIRI/cetuximab to FOLFIRI/cetuximab for eight cycles followed by cetuximab alone in first-line treatment of RAS and BRAF (wt) metastatic colorectal cancer patients.